[go: up one dir, main page]

HUP9904075A2 - Composition, for the treatment of asthma,containing loratadine and a decongestant - Google Patents

Composition, for the treatment of asthma,containing loratadine and a decongestant

Info

Publication number
HUP9904075A2
HUP9904075A2 HU9904075A HUP9904075A HUP9904075A2 HU P9904075 A2 HUP9904075 A2 HU P9904075A2 HU 9904075 A HU9904075 A HU 9904075A HU P9904075 A HUP9904075 A HU P9904075A HU P9904075 A2 HUP9904075 A2 HU P9904075A2
Authority
HU
Hungary
Prior art keywords
decongestant
asthma
treatment
composition
containing loratadine
Prior art date
Application number
HU9904075A
Other languages
Hungarian (hu)
Inventor
Alan G. Harris
Original Assignee
Schering Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp. filed Critical Schering Corp.
Publication of HUP9904075A2 publication Critical patent/HUP9904075A2/en
Publication of HUP9904075A3 publication Critical patent/HUP9904075A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya lőratidint és egy decőngestanst, példáűlpszeűdőefedrint tartalmazó készítmény alkalmazása asztmában szenvedőbeteg pűlmőnáris fűnkciójának javítására. A hatóanyag-kőmbinációbeadásának köszönhetően statisztikűsan jelentős javűlást észlelnek azerőltetett kilégzési térfőgat (FEV) és a csúcskilégzési áram (PEF)értékeiben. ŕThe subject of the invention is the use of a preparation containing loratidine and a decongestant, for example ephedrine, to improve the pulmonary function of a patient suffering from asthma. Due to the administration of the active substance-calcium combination, a statistically significant improvement is observed in the forced expiratory volume (FEV) and peak expiratory flow (PEF) values. ŕ

HU9904075A 1996-10-31 1997-10-29 Composition, for the treatment of asthma,containing loratadine and a decongestant HUP9904075A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73966996A 1996-10-31 1996-10-31

Publications (2)

Publication Number Publication Date
HUP9904075A2 true HUP9904075A2 (en) 2000-05-28
HUP9904075A3 HUP9904075A3 (en) 2002-02-28

Family

ID=24973307

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904075A HUP9904075A3 (en) 1996-10-31 1997-10-29 Composition, for the treatment of asthma,containing loratadine and a decongestant

Country Status (21)

Country Link
EP (1) EP0941091A1 (en)
JP (1) JP2000505104A (en)
KR (1) KR20000052922A (en)
CN (1) CN1235545A (en)
AR (1) AR008908A1 (en)
AU (1) AU731756B2 (en)
BR (1) BR9712705A (en)
CA (1) CA2268546A1 (en)
CO (1) CO4910128A1 (en)
CZ (1) CZ150999A3 (en)
HU (1) HUP9904075A3 (en)
ID (1) ID23431A (en)
IL (1) IL129662A0 (en)
NO (1) NO992062D0 (en)
NZ (1) NZ335078A (en)
PE (1) PE11399A1 (en)
PL (1) PL333056A1 (en)
SK (1) SK54599A3 (en)
TR (1) TR199901003T2 (en)
WO (1) WO1998018470A1 (en)
ZA (1) ZA979731B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1205799A (en) * 1997-10-29 1999-05-17 J-Med Pharmaceuticals, Inc. Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
IT1303671B1 (en) * 1998-07-28 2001-02-23 Nicox Sa SALTS OF NITRIC ACID WITH ACTIVE DRUGS IN THE TREATMENT OF DISEASES OF THE RESPIRATORY SYSTEM
PE20001070A1 (en) * 1998-09-10 2000-10-19 Schering Corp METHODS AND COMPOSITIONS TO TREAT SINUSITIS, OTITIS MEDIA AND OTHER RELATED DISORDERS USING ANTIHISTAMINES
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
KR100505899B1 (en) * 1999-02-23 2005-08-01 주식회사유한양행 Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
EP1154762B1 (en) * 1999-02-23 2003-11-05 Yuhan Corporation Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
WO2000057880A1 (en) * 1999-03-29 2000-10-05 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
WO2001078782A1 (en) * 2000-04-14 2001-10-25 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
BR0111018A (en) * 2000-05-25 2004-02-17 Schering Corp Liquid and solid stable formulations
MXPA03011705A (en) * 2001-06-20 2004-03-19 Schering Corp Antihistamines for the treatment of nasal congestion and nasal obstruction.
RU2423979C2 (en) * 2005-06-17 2011-07-20 АФТ Фармасьютикалз Лимитед Novel pharmaceutic composition and its application in method of treatment of patients with hyperaemia and edema of mucous membrane of upper airways
NZ588134A (en) 2005-06-17 2010-11-26 Aft Pharmaceuticals Ltd Novel pharmaceutical for use in a method for treatment of upper respiratory mucosal congestion
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
NZ573173A (en) * 2006-06-01 2012-03-30 Msd Consumer Care Inc Phenylephrine pharmaceutical formulation and compositions for colonic absorption
KR101540191B1 (en) * 2014-02-24 2015-07-28 성균관대학교산학협력단 Composition comprising Loratadine for anti-inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1110397A (en) * 1964-10-02 1968-04-18 Mead Johnson & Co Ephedrine composition
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Also Published As

Publication number Publication date
SK54599A3 (en) 2000-08-14
NO992062L (en) 1999-04-29
AU731756B2 (en) 2001-04-05
CN1235545A (en) 1999-11-17
EP0941091A1 (en) 1999-09-15
NZ335078A (en) 2000-10-27
NO992062D0 (en) 1999-04-29
JP2000505104A (en) 2000-04-25
CA2268546A1 (en) 1998-05-07
BR9712705A (en) 1999-10-26
PE11399A1 (en) 1999-02-09
PL333056A1 (en) 1999-11-08
CZ150999A3 (en) 1999-10-13
ID23431A (en) 2000-04-20
AU4995397A (en) 1998-05-22
HUP9904075A3 (en) 2002-02-28
KR20000052922A (en) 2000-08-25
TR199901003T2 (en) 1999-07-21
CO4910128A1 (en) 2000-04-24
IL129662A0 (en) 2000-02-29
WO1998018470A1 (en) 1998-05-07
ZA979731B (en) 1998-04-29
AR008908A1 (en) 2000-02-23

Similar Documents

Publication Publication Date Title
HUP9904075A2 (en) Composition, for the treatment of asthma,containing loratadine and a decongestant
BG102022A (en) DOSING INHALATOR FOR SALMETEROL
HUP0301349A2 (en) Formulations for il-11
DK0613371T3 (en) New combination of formoterol and budesonide
YU59092A (en) FORMULATIONS OF AEROSOLS NOT CONTAINING CHLOROFLUORO-CARBON COMPOUNDS
IL125534A (en) Unit dose of budesonide and use thereof for nasal administration
EE200000329A (en) Oral Form For Acid-Unstable Active Ingredients, Method Of Preparation And Use Of A Unit Of Acid-Unstable Active Ingredient
EP1201242A3 (en) Use of mometasone furoate in an adjuvant therapy
IS2788B (en) Budesonide / formoterol formulation for inhalation at a free concentration of 0.30 to 0.36 g / ml, method of preparation and use of the preparation
PT893992E (en) FORMS OF FAST DISINTEGRATION ORAL DOSAGE
TR200002855T2 (en) Administration of raloxifene via the respiratory tract or nose.
HUP0301868A2 (en) Pharmaceutical composition comprising a factor viia and a factor xiii
HUP0102728A2 (en) Methods and transdermal compositions for pain relief
HUP0000873A2 (en) The use of levobupivacaine in facial surgery
EE03385B1 (en) Use of Angiotensin Type II Receptor Antagonists for the preparation of a medicament for the prophylaxis and / or treatment of dyspeptic symptoms and pharmaceutical preparations containing angiotensin II type 1 receptor antagonists
NO943288L (en) Use of pentoxyphylline in the preparation of pharmaceutical preparations for the treatment of granulomatosis and fibrosis lung disease
ATE271852T1 (en) IMPROVED INHALATION PREPARATIONS
ES2176805T3 (en) USE OF MIXTURES OF ACTIVE PRODUCTS FOR THE OBTAINING OF HYPOCOLESTERINEMIC AGENTS.
EE04330B1 (en) Transmucosal formulations of levosimendan and their use in the manufacture of a medicament
SE9902597D0 (en) New use
ES2131482A1 (en) An aqueous formulation comprising bambuterol and the use thereof
HUP0301408A2 (en) Methods and compositions using sulodexide for the treatment of diabetic nephropathy
Schoenbaum Developing effective systems for delivery of vaccines
MD1051C2 (en) Antiherpetic remedy
MD1469G2 (en) Method of treatment of the burn shock